RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • SCOPUSKCI등재

        과민성 대장증후군에 대한 Trimebutin Maleate ( PolybutineR ) 서방정 및 속방정의 비교 임상연구 (

        함준수(Joon Soo Hahm),이동후(Dong Hoo Lee),기춘석(Choon Suhk Kee),박경남(Kyung Nam Park),이민호(Min Ho Lee),이종철(Jong Chul Rhee),이상(Sahng Lee),윤석진(Suhk Jeen Yoon) 대한소화기학회 1993 대한소화기학회지 Vol.25 No.6

        N/A The purpose of this paper is to evaluate the clinical effectiveness of Trimebutine maleate in the treatment of patients with irritable bowel syndrome, the total number of subjects was 55 patients (male: 31 cases, female: 24 cases) who had been visited to Hanyang university hospital, Among them, 30 cases were treated with trimebutine maleate(300 mg) twice daily (Drug A) and 25 cases with trimebutine maleate(200mg) three times daily (Drug B). Drug A and drug B were administered randomly to each assigned group, and symptoms were scored before and after the study. The results were as follows: Initial symptorns of patients with drug A were appeared as abdominal distension(92.8%), abdominal pain(92.6%), constipation(90%) and diarrhea(89.5%) ancl 91.3%, 90.0%, 88.9% and 86.4%, respective]y in patients with drug B The effective rate of trimebutine maleate (drug A & B) on each symptoms were 92.8%, 91.3%(abdominal distension), 92.6%, 90.0% (abdominl pain) 90.0%, 86.4% (constipation) 89.5%, 88.9% (diarrhea) and 85.7%, 87.5%(vomiting) respectively, and there are no differences in the effectiveness of subjective symptoms between each groups. The result of evaluation of the overall effectiveness of trimebutine maleate (Drug A & B) were 90.0% & 92.0% and there are no differences of overall effectiveness, between each group. No serious adverse drug reactions were noted with each group. Considering the effectiveness of the two regimens which do not show statistical differences, trimebutine maleate 330mg twice daily is preferable in the treatment of patient, with irritable bowel syndrome in terms of convenience.

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼